Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Advanced Accele. Ads (AAAP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 3,107,187
  • Shares Outstanding, K 43,980
  • Annual Sales, $ 120,980 K
  • Annual Income, $ -27,990 K
  • 36-Month Beta 0.94
  • Price/Sales 25.89
  • Price/Cash Flow 0.00
  • Price/Book 9.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.00 +33.30%
on 09/22/17
72.93 -3.13%
on 10/17/17
+13.02 (+22.59%)
since 09/18/17
3-Month
39.78 +77.60%
on 07/19/17
72.93 -3.13%
on 10/17/17
+30.81 (+77.33%)
since 07/18/17
52-Week
23.50 +200.64%
on 12/22/16
72.93 -3.13%
on 10/17/17
+31.76 (+81.67%)
since 10/18/16

Most Recent Stories

More News
Advanced Accelerator (AAAP) Cancer Therapy Approved in EU

Advanced Accelerator Applications' (AAAP) Lutathera gets approval in Europe as its first radionuclide therapy for the treatment of tumors in the gut.

SPPI : 19.67 (+36.03%)
BAYRY : 35.1100 (+0.14%)
AAAP : 70.65 (-0.83%)
GSK : 41.01 (+0.44%)
Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera(R)) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the European Commission (EC) has approved...

AAAP : 70.65 (-0.83%)
Earnings Review and Free Research Report: Advanced Accelerator's Revenue Increased 32%

Research Desk Line-up: Neogen Post Earnings Coverage

AAAP : 70.65 (-0.83%)
NEOG : 78.80 (+2.51%)
CORRECTING and REPLACING -- Advanced Accelerator Applications S.A.

In a release issued earlier today by Advanced Accelerator Applications S.A. (NASDAQ:AAAP), please note that the headline has been updated to omit FUJIFILM RI Pharma, Co., LTD. The corrected headline...

AAAP : 70.65 (-0.83%)
Advanced Accelerator Applications (AAAP) in Focus: Stock Moves 7.5% Higher

Advanced Accelerator Applications S.A. (AAAP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

AAAP : 70.65 (-0.83%)
CRBP : 7.00 (-0.71%)
Advanced Accelerator Applications and FUJIFILM RI Pharma, Co., LTD Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate* (Lutathera(R))

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the first patient has been treated in a...

AAAP : 70.65 (-0.83%)
Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017

Positive CHMP Opinion for Lutetium Lu 177 Dotatate* (Lutathera) for GEP-NETS

AAAP : 70.65 (-0.83%)
Advanced Accelerator Gets Action Date for Lutathera from FDA

The FDA granted an action date for Lutathera after the company resubmitted the New Drug Application (NDA) for the candidate.

AAAP : 70.65 (-0.83%)
REGN : 439.37 (-0.72%)
ADRO : 9.55 (-1.04%)
ALXN : 140.24 (-2.04%)
Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera(R))

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the US Food and Drug Administration (FDA)...

AAAP : 70.65 (-0.83%)
Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment

Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment

AAAP : 70.65 (-0.83%)
ENTA : 47.30 (-0.94%)
NYT : 19.15 (+0.52%)
CMCO : 37.24 (+0.24%)
CZR : 12.30 (+3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company's commercial products...

See More

Support & Resistance

2nd Resistance Point 72.48
1st Resistance Point 71.56
Last Price 70.65
1st Support Level 69.91
2nd Support Level 69.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart